Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A. Marzinke, Susan H. Eshleman, Ryann Gollings et al.|Antimicrobial Agents and Chemotherapy|2023Cited by 30
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Brett Hanscom et al.|The Lancet HIV|2023Cited by 14
A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEPYifan Yu, Kristin L. Bigos, Mark A. Marzinke et al.|British Journal of Clinical Pharmacology|2022Cited by 11
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialAdeola Adeyeye, Zhe Wang, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 0